Outcome Capital Promotes Thomas Busby to Director to Expand Medical Device and Life Science Services Practices

2024-01-11

高管变更

BOSTON--(BUSINESS WIRE)--Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Thomas F. Busby has been promoted to Director at Outcome’s Boston office. Mr. Busby, formerly Senior Vice President at Outcome, will focus on the medical device, digital health and life science services verticals within Outcome’s unique strategy-driven platform, providing M&A, capital raising and advisory services to his clients.

'Beyond knowing the market and our technology as well as anyone, Thom\u2019s authenticity and calm, yet relentless, focus makes him unique. He is someone you want to have in your corner, advocating and advising on your and your shareholders\u2019 behalf.'

“The climate is right for life science dealmaking as we head into 2024, and Thom’s experience, expertise and integrity have long been lauded by our clients. Thom’s promotion will directly benefit Outcome’s clients and is in-line with our continued commitment to the advancement of life science technologies, as well as our teams’ professional development,” said Co-Founders and Managing Partners Dr. Oded Ben-Joseph and Arnold Freedman.

Mr. Busby joined Outcome Capital in 2015 and has advised dozens of management teams throughout the life sciences spectrum. Having advised on biopharma, medical device, diagnostics, laboratory, healthcare IT, and outsourced services mandates, Mr. Busby’s clients benefit from the breadth of his experience and his deep sector knowledge. During his time with Outcome Capital, Mr. Busby oversaw numerous private equity and debt placements, in addition to executing a variety of strategic M&A transactions with both public and private buyers and sellers.

Chris Mathia, former CEO of Innara Health, Inc. and a past client of Mr. Busby’s, commented, “Beyond knowing the market and our technology as well as anyone, Thom’s authenticity and calm, yet relentless, focus makes him unique. He is someone you want to have in your corner, advocating and advising on your and your shareholders’ behalf.”

Outside of Mr. Busby’s transactional work, he is a Board Member of HealthTech Build, a Boston-based digital health trade group, and a frequently published author in leading medical device and life science trade journals. He holds both an MBA and BS from Suffolk University and previously worked in the non-profit and philanthropic sectors.

“First and foremost, I am excited to continue to serve and work with our industry’s leading founders and innovators, and provide world-class strategic and financial advice. It has been my pleasure to grow alongside Outcome Capital, and in this new role I look forward to continuing this trajectory,” commented Mr. Busby.

About Outcome Capital

Outcome Capital (outcomecapital.com) is a highly specialized life sciences and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构